NCT06322329 RealMove (Lung): Assessing Tumour Motion With Dynamic MRI
| NCT ID | NCT06322329 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Stockholm |
| Condition | Lung Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-03-15 |
| Primary Completion | 2026-03-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-03-15 with a primary completion date of 2026-03-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to develop an improved method to tailor the geometric safety margin when treating with stereotactic body radiotherapy (SBRT), to avoid tumour cells being missed during irradiation and to limit the exposure of normal tissues as much as possible. Dynamic magnetic resonance imaging (MRI) is assumed to represent the tumour motion during the respiratory cycle more realistically, compared to 4-dimensional computed tomography (4D CT), thanks to its high temporal resolution and the possibility to image the motion over a longer period of time. Patients receiving SBRT for a pulmonary target located below the level of the carina are included in the study, and the hypothesis will be tested through a comparison of the tumour amplitude measured with each modality. Furthermore, the predictive value of the image series acquired at treatment planning, for the motion patterns observed at each treatment fraction, will be evaluated through repeated 4D CBCT acquisitions.
Eligibility Criteria
Inclusion Criteria: * Accepted for SBRT treatment of one or more caudally situated lung targets (NSCLC or metastases), i.e. below the carina. * Age ≥ 18 years * Adequate clinical condition to maintain immobilised position for at least 30 minutes * Adequate Swedish skills and cognitive function to understand study information and to fill in the questionnaire Exclusion Criteria: * Pregnancy or breastfeeding, or planned pregnancy or breastfeeding, during treatment * Contraindication for MRI examination * Otherwise incapable of participating in study
Contact & Investigator
Eva Onjukka, PhD
PRINCIPAL INVESTIGATOR
Karolinska University Hospital/Karolinska Institutet
Frequently Asked Questions
Who can join the NCT06322329 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06322329 currently recruiting?
Yes, NCT06322329 is actively recruiting participants. Contact the research team at mattias.hedman@regionstockholm.se for enrollment information.
Where is the NCT06322329 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT06322329 clinical trial?
NCT06322329 is sponsored by Region Stockholm. The principal investigator is Eva Onjukka, PhD at Karolinska University Hospital/Karolinska Institutet. The trial plans to enroll 150 participants.